Devyser Diagnostics AB
Devyser Diagnostics AB (publ) engages in the development, manufacture, and sale of diagnostic kits and solutions for DNA testing within hereditary diseases, oncology, and post-transplantation monitoring in Sweden, rest of Europe, the Middle East, Africa, North and South America, and Asia. The company offers products in the areas of post-transplantation; thalassemia; breast, colorectal, and ovaria… Read more
Devyser Diagnostics AB (DVYSR) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.000x
Based on the latest financial reports, Devyser Diagnostics AB (DVYSR) has a cash flow conversion efficiency ratio of 0.000x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-100.00K) by net assets (Skr340.90 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Devyser Diagnostics AB - Cash Flow Conversion Efficiency Trend (2018–2024)
This chart illustrates how Devyser Diagnostics AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Devyser Diagnostics AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Devyser Diagnostics AB ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
0.385x |
|
Generalplus Technology Inc
TW:4952
|
0.069x |
|
Fu Chun Shin Machinery Manufacture Co Ltd
TWO:6603
|
0.081x |
|
Spheria Emerging Companies Ltd
AU:SEC
|
0.041x |
|
ELECO PLC LS-01
F:5H3
|
N/A |
|
402490
KQ:402490
|
-0.066x |
|
Lavipharm S.A
AT:LAVI
|
0.010x |
|
RideNow Group, Inc.
NASDAQ:RDNW
|
0.037x |
Annual Cash Flow Conversion Efficiency for Devyser Diagnostics AB (2018–2024)
The table below shows the annual cash flow conversion efficiency of Devyser Diagnostics AB from 2018 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr349.00 Million | Skr-46.80 Million | -0.134x | +25.91% |
| 2023-12-31 | Skr385.10 Million | Skr-69.70 Million | -0.181x | -92.80% |
| 2022-12-31 | Skr431.44 Million | Skr-40.50 Million | -0.094x | -137.32% |
| 2021-12-31 | Skr416.68 Million | Skr-16.48 Million | -0.040x | -294.14% |
| 2020-12-31 | Skr30.77 Million | Skr627.00K | 0.020x | -94.85% |
| 2019-12-31 | Skr37.01 Million | Skr14.63 Million | 0.395x | +96.80% |
| 2018-12-31 | Skr29.97 Million | Skr6.02 Million | 0.201x | -- |